Activity Date: 04/07/2019
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this course.
To receive ACPE credit for the live session at the Annual Meeting, you must:
This course is provided on-site at the 2019 CPNP Annual Meeting. To earn ACPE credit, participants must attend the full learning activity, participate actively through pre- and post-tests, and complete an online evaluation.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Patrick Finley, PharmD, BCPP
Leslie Citrome, MD, MPH
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.5 contact hours of knowledge-based continuing education credit from CPNP approved programming. The ACPE number is 0284-9999-19-060-L01-P.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
Mary Borovicka, PharmD, BCPP
Associte Professor
University of Toledo
Cleveland, OH
Employer and Position: University of Toledo College of Pharmacy and Pharmaceutical Sciences
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.
Company and Activities/Services You Provided: Ohio Pharmacists Association - LAI and naltrexone training inj
Steve Stoner, PharmD, BCPP
Clinical Professor and Chair
University of MO at KC School of Pharmacy
Kansas City, MO
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc. Neurocrine Speaker's Bureau, Otsuka Speaker's Bureau, Alkermes Advisory Panel
Educational Grants, Research Grants or Contracts: Alkermes Supported Research Grant Funding
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices. Please indicate drugs and/or devices here: ketamine; esketamine; psilocybin; d-cycloserine; rapastinel; SAGE-547 (brexanolone); SAGE-217; ALKS 5461 (buprenorphine + samidorphan); deep transcranial magnetic stimulation (DTMS); repetitive transcranial magnetic stimulation (rTMS); synchronized transcranial magnetic stimulation (sTMS); low field magnetic stimulation (LFMS); scopolamine; onabotulinumtoxin A; mifepriston; metyrapone; org-34517; AXS 05 (dextro-methorphan + bupropion); nitrous oxide
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
Offered by
Neuroscience Education Institute; ACPE accreditation provided by CPNP.
Supported by
Alkermes
